06 Sep 2021 Avacta announces new appointments to the Scientific Advisory Board of its Therapeutics Division Investors | Therapeutics
02 Sep 2021 Appointment of Dr Fiona McLaughlin as Chief Scientific Officer of Avacta’s Therapeutics Division Investors | Therapeutics
11 Aug 2021 Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase 1 Clinical Trial Investors | Therapeutics
29 Jun 2021 AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Detects Delta Variant Diagnostics | Investors
21 Jun 2021 AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Distribution Agreement Diagnostics | Investors